Neumora Q2 FY26 net loss narrows to $43.1 million
NMRA•Pipeline milestones
Pipeline milestones include:
- NMRA-215 IND planned for Q4 2026
- NMRA-511 data expected Q4 2026
- NMRA-898 data due in H2 2026
Cash position and runway
Cash and cash equivalents totaled $116.8 million at June 30, expected to fund operations into Q3 2027.
Net loss narrows in Q2 FY26
Neumora posted a GAAP net loss of $43.1 million, narrowing from $52.7 million a year earlier.
R&D expense fell 24.33% to $29.3 million, due to lower clinical trial costs and reduced personnel-related costs.
G&A expense dropped 15.77% to $12.9 million on lower personnel-related costs.
